RT Book, Section
A1 Bagatell, Rochelle
A1 Meany, Holly
A2 Kline, Mark W.
SR Print(0)
ID 1182911494
T1 Neuroblastoma
T2 Rudolph's Pediatrics, 23e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259588594
LK accesspediatrics.mhmedical.com/content.aspx?aid=1182911494
RD 2024/04/23
AB Neuroblastoma,  a  tumor  of  the  sympathetic  nervous  system,  is  the  most  common  extra-cranial  solid  tumor  of  childhood.  Neuroblastoma  is  a  clinically  heterogeneous  disease,  as  infants  with  metastatic  disease  may  experience  complete  tumor  regression  without  therapy,  while  other  children  may  experience  relentless  disease  progression  despite  modern  multimodality  therapy.  Current  risk  classification  schemes  use  clinical,  histologic,  and  genomic  features  at  diagnosis  to  predict  tumor  behavior  and  to  assign  patients  to  an  appropriate  treatment  regimen  based  on  risk  of  recurrence.  Children  with  lower  risk  disease  are  spared  unnecessary  therapies  yet  still  achieve  excellent  outcomes.  Nevertheless,  outcome  remains  poor  for  patients  classified  as  high  risk.  Additionally,  survivors  of  high-risk  neuroblastoma  are  at  risk  for  significant  treatment-related  adverse  events,  emphasizing  the  critical  need  for  more  effective,  less  toxic  treatments.  A  better  understanding  of  the  molecular  pathogenesis  of  neuroblastoma,  including  an  understanding  of  how  alterations  in  specific  biological  pathways  impact  tumor  behavior,  may  lead  to  improved  treatments.